Matthew Gline - 24 Feb 2025 Form 3 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Director, 10%+ Owner
Signature
/s/ David C. Hastings as attorney-in-fact for Matthew Gline
Issuer symbol
ABUS
Transactions as of
24 Feb 2025
Net transactions value
$0
Form type
3
Filing time
06 Mar 2025, 16:07:01 UTC
Previous filing
24 Feb 2025
Next filing
24 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABUS Common Shares 38,847,462 24 Feb 2025 By Roivant Sciences Ltd. F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is the Principal Executive Officer and a director of Roivant Sciences Ltd. (''Roivant'') and may be deemed to have beneficial ownership of the securities of the Issuer held by Roivant. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit 24: Power of Attorney